drug · protein
etelcalcetide hydrochloride
Marketedupdated 3mo agoby $AMGN AMGEN INC🔗 ChEMBL
Approvedcommunity read0 votes
Protein drug with a maximum clinical stage of Approval (across all indications), with an approval for secondary hyperparathyroidism and chronic kidney disease.
targets
Extracellular calcium-sensing receptor
all catalysts(0)
nothing on the calendar yet
Trials studying etelcalcetide hydrochloride
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jul 29, 2030
~3.9 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (24)
- Jun 27, 2034formulationUS 10344765
- Jun 27, 2034formulationUS 10344765
- Jun 27, 2034formulationUS 10344765
- Jun 27, 2034formulationUS 11162500
- Jun 27, 2034formulationUS 11162500
- Jun 27, 2034formulationUS 11162500
- Jun 27, 2034formulationUS 11959486
- Jun 27, 2034formulationUS 11959486
- Jun 27, 2034formulationUS 11959486
- Jun 27, 2034formulationUS 9820938
- Jun 27, 2034formulationUS 9820938
- Jun 27, 2034formulationUS 9820938
- Feb 7, 2031compositionUS 89999324.5y
- Feb 7, 2031compositionUS 89999324.5y
- Feb 7, 2031compositionUS 89999324.5y
- Jul 29, 2030compositionUS 83778803.9y
- Jul 29, 2030compositionUS 83778803.9y
- Jul 29, 2030compositionUS 83778803.9y
- Jul 29, 2030compositionUS 92789953.9y
- Jul 29, 2030compositionUS 92789953.9y
- Jul 29, 2030compositionUS 92789953.9y
- Jul 29, 2030compositionUS 97017123.9y
- Jul 29, 2030compositionUS 97017123.9y
- Jul 29, 2030compositionUS 97017123.9y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 27m ago
Found something off?
comments(0)
5-min edit window · permanent after that